Editorial: regulation of inflammation, its resolution and therapeutic targeting by Uguccioni, Mariagrazia et al.
April 2017 | Volume 8 | Article 4151
Editorial
published: 18 April 2017
doi: 10.3389/fimmu.2017.00415
Frontiers in Immunology | www.frontiersin.org
Edited and Reviewed by: 
Pietro Ghezzi, 
Brighton and Sussex 
Medical School, UK
*Correspondence:
Mariagrazia Uguccioni  
mariagrazia.uguccioni@irb.usi.ch
Specialty section: 
This article was submitted to 
Inflammation, 






Uguccioni M, Teixeira MM, Locati M 
and Mantovani A (2017) Editorial: 
Regulation of Inflammation, 
Its Resolution and 
Therapeutic Targeting. 
Front. Immunol. 8:415. 
doi: 10.3389/fimmu.2017.00415
Editorial: regulation of inflammation, 
its resolution and therapeutic 
targeting
Mariagrazia Uguccioni1*, Mauro Martins Teixeira2, Massimo Locati3,4 and  
Alberto Mantovani3,5
1 Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland, 2 Laboratorio de 
Imunofarmacologia, Departamento de Bioquimica e Imunologia, Instituto de Ciencias Biologicas, Universidade Federal de 
Minas Gerais, Belo Horizonte, Brazil, 3 Humanitas Clinical and Research Center, Rozzano, Italy, 4 Department of Medical 
Biotechnologies and Translational Medicine, University of Milan, Milan, Italy, 5 Humanitas University, Rozzano, Italy
Keywords: regulation, inflammation, therapeutic targeting, cell migration, tlr
Editorial on the Research Topic
Regulation of Inflammation, Its Resolution and Therapeutic Targeting
Inflammation underlies the pathogenesis of diverse human diseases ranging from infection, 
immune-mediated disorders to cardiovascular pathology, neurodegeneration, and cancer. Progress 
in the field of immunity and inflammation has led to a change in paradigm concerning resolu-
tion. Resolution has emerged as an integrated actively orchestrated process with multiple players. 
These include metabolites of the arachidonic acid cascade, anti-inflammatory cytokines, decoy, and 
scavenger receptors. Inflammatory cells undergo genetic reprograming during resolution with for 
instance orientation of macrophages to a pro-resolving mode. Failure of resolution has emerged as 
a fundamental mechanism of disease. Smoldering non-resolving inflammation is, for instance, an 
essential constituent of the tumor microenvironment. Under self-limiting conditions, inflammation 
spontaneously resolves in an active process. Some cellular and molecular mechanisms involved in 
inflammation resolution have been uncovered in the recent past and include generation of specific 
cytokines, apoptosis of inflammatory leukocytes, lipid mediators, macrophage repolarization, and 
others are likely to be revealed in the next future, since loss-of-function mutations of an increasing 
number of genes results in the development of spontaneous inflammation in experimental animals. 
“Pushing for” resolution of inflammation by exploiting active naturally occurring pro-resolving 
processes may have significant advantages over the attempt to simply “push back” inflammation by 
passive blockade of pro-inflammatory mediators.
This Topic of Frontiers offers the reader views on key aspects of the regulation of resolution 
of inflammation. Its foundations lay in the European Union supported project TIMER (Targeting 
novel mechanisms of resolution in inflammation)1 and the effort of the International Union of 
Immunological Societies (IUIS)2 that have fostered the collaboration of several groups in Europe 
and Brazil, supporting the preclinical work on molecules and mechanisms involved in resolution of 
inflammation as a basis for the development of innovative therapeutic strategies in chronic inflam-
mation and autoimmune disease. These studies have been laid the foundations in the clinical trials 
that have been initiated.
The topic is placed in the context set by a review from Sugimoto et al. that focuses on the events 
required for an effective transition from the pro-inflammatory phase to the onset and establishment of 
1 http://www.eumbrella.org/.
2 http://www.iuisonline.org/.
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resolution, suggesting that the mediators promoting inflammation 
can simultaneously propel the program for an active resolution. 
A set of articles then focus on specific molecular players involved 
in this process. Molgora et  al. summarize evidence indicating 
IL-1R8 as a key anti-inflammatory molecule, which needs further 
investigation in human pathology as its targeting holds promise 
of innovative therapies in several inflammatory conditions. Alves-
Filho and Palsson-McDermott review expression and enzymatic 
activities of PKM2 that can be regulated at multiple levels, 
including transcription, posttranslational modifications, and 
allosteric regulation of conformational stability. PKM2 represents 
a novel potential target for the development of anti-inflammatory 
drugs, as recent studies have unraveled a notable involvement 
of PKM2 in controlling the transcriptional activity of HIF-1α 
and STAT3 pathways during inflammation (Alves-Filho and 
Palsson-McDermott). Still on STAT3, Muhl reviews the preclini-
cal data suggesting that providing recombinant STAT3-activating 
cytokines directly targeting hepatocytes, especially IL-11 and 
IL-22, may evolve as additional novel pro-regenerative therapeu-
tic option in hard-to-treat patients where standard therapy with 
N-acetylcysteine alone falls short. Notably, the benefit of focused 
short-term application of IL-11 or IL-22 in acute disorders, such 
as APAP-induced ALI, should likely outweigh the inherent danger 
of these cytokines to promote in the long run tumor growth, 
which has been detected for IL-22 and hepatocellular carcinoma 
patients (Muhl). Proudfoot and Uguccioni discuss how synergy 
between chemokines or DAMP molecules, together with the low-
affinity interaction with GAGs can tune the response of leukocytes 
to chemokines, controlling leukocyte extravasation into damaged 
or inflamed tissues. Dampening inflammation targeting the 
chemokine system can be achieved either targeting chemokines 
or their receptors. Blood-sucking parasites inhibit the recruit-
ment of immune cells by producing a class of chemokine-binding 
proteins known as Evasins, whose advantages and disadvantages 
for potential development for therapeutic use is here discussed 
by Bonvin et  al. On the receptor side, allosteric antagonists of 
chemokine receptors, discussed by Allegretti et al., might provide 
both functional selectivity and probe/concentration depend-
ence. Vertebrates have adopted a number of mechanisms for 
removing chemokines from inflamed sites to help precipitate 
resolution. Over the past 15 years, it has become apparent that 
essential players in this process are the members of the atypical 
chemokine receptor (ACKR) family. Broadly speaking, this fam-
ily is expressed on stromal cell types and scavenges chemokines 
to either limit their spatial availability or to remove them from 
in vivo sites. Here, Bonecchi and Graham provide a brief review 
of these ACKRs and discuss their involvement in the resolution of 
inflammatory responses and the therapeutic implications of our 
current knowledge. Resolution of inflammation also requires a 
functional switch in inflammatory cells biology. Neutrophils are 
classically considered to be essential players in the host defense 
against invading pathogens. However, several investigations have 
shown that impairment of neutrophil migration to the site of 
infection, also referred to as neutrophil paralysis, occurs during 
severe sepsis, resulting in an inability of the host to contain and 
eliminate the infection. On the other hand, the neutrophil anti-
bacterial arsenal contributes to tissue damage and the develop-
ment of organ dysfunction during sepsis. Sônego et al. provide an 
overview of the main events in which neutrophils play a beneficial 
or deleterious role in the outcome of sepsis. Finally, Ferreira et al. 
provide a comprehensive comparison of the anti-inflammatory 
effectiveness of two PEGylated TLR7 partial agonists, concerning 
distinct lung pathological conditions and several routes of admin-
istration. The results suggest that the putative clinical application 
of TMX-302 in lung disorders should be examined with caution 
because of its direct pro-inflammatory effects. Moreover, in this 
context, TMX-306 seems to be comparatively more effective and 
safer than TMX-302, deserving further investigations in drug 
development particularly for silicosis (Ferreira et al.).
The increasing number of anti-inflammatory drugs best sellers 
in the pharma market is a clear indication of the relevance of 
having inflammation under check; nonetheless, there is still a 
great need for better acting pharmacological tools for the control 
of inflammation. Indeed, the remarkable success of biological 
drugs targeting pro-inflammatory cytokines has indicated that 
tools able to block pro-inflammatory mediators have promising 
applications. However, there are intrinsic limitations of single 
targeting drugs because effects frequently vanish, likely due to 
the well-known redundancy of inflammatory mediators. TIMER 
has investigated a number of players with potential of developing 
as innovative targets in this setting and “will not end with the end 
of dedicated European funding in December 2015, as the legacy 
of this EU-funded project endures in the preclinical work and 
in the collaboration that has been fostered,” as his coordinator 
concluded in the TIMER final meeting.
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